Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 1898917Search this ID in NIH RePORTER
- ScienceDex PI coverage
- FY2024 through FY2026Career claims are limited to the years shown.
FY2026 award categories
- Internal Medicine
NIH Funding · FY2025
Linked Award Amount
$3.4M
Full award amounts, FY2025
Award Records
4
Records listing this PI
Award-Linked Rank
#2,725
By linked amount among FY2025 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2025 award records by amount
NIH award records listing Donald W. Kufe as a PI. Multi-PI records show the full award amount for context.
- 5UM1CA186709-09UM1Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)$2.1Maward amount
- 5R01CA282437-02R01Combining CDK7 and MUC1-C inhibition to target different subtypes of small cell lung cancer$673.9Kaward amount
- 5R01CA097098-21R01Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer$462.3Kaward amount
- 3UM1CA186709-09S1UM1DF/HCC Preclinical Translation-Focused Clinical Investigator to Bridge PDXNet and the ETCTN$194.2Kaward amount
Award organizations
Organizations that administered FY2025 awards listing Donald W. Kufe as a PI.
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardDana-Farber Cancer Institute
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2024$2M Cumulative Funding
- 2024Entered Top 50% NationallyRanked #1910
- 2024Entered Top 25% NationallyRanked #1910
- 2024Entered Top 10% NationallyRanked #1910
- 2025$5M Cumulative Funding
- 2025Multi-Institutional ResearchAwards at 2 institutions
- 2025R01 Grant Holder
- 2026$10M Cumulative Funding
Shared-award investigators
Other investigators listed on at least one of the same NIH award records as Donald W. Kufe.